Raffaella Faraoni's practice focuses on patent prosecution, including drafting and prosecuting U.S. and foreign patent applications relating to small-molecule therapeutics, medicinal chemistry, drug formulation, and other areas of drug discovery. Raffaella assists Idenix Pharmaceuticals (now Merck), Puma Biotechnology, Neurocrine Biosciences, and Rana Therapeutics. She has experience in preparing and prosecuting patent applications throughout the world, assisting in oppositions proceedings, and in conducting patentability and freedom-to-operate analysis.
Prior to joining Jones Day, Raffaella worked as a medicinal chemist at Ambit Biosciences and the Genomic Institute of the Novartis Research Foundation (GNF), where her research area focused on the design and synthesis of kinase and ion channels small molecule inhibitors for the treatment of cancer and chronic pain.
Raffaella's academic research spanned from molecular recognition to the total synthesis of natural products and included working with Professor K.C. Nicolaou at The Scripps Research Institute, where she focused on the total synthesis of natural products. She is coauthor of several peer-reviewed scientific articles and a co-inventor of a number of issued patents and patent applications.
Experience
Takeda acquires Ariad Pharmaceuticals for $5.2 billion
Jones Day advised Takeda Pharmaceuticals U.S.A., Inc. on intellectual property matters relating to its $5.2 billion acquisition of Ariad Pharmaceuticals.
Idenix establishes patent portfolio related to nucleoside analog antiviral drugs
Jones Day represents Idenix Pharmaceuticals, Inc. in the management and development of a patent portfolio related to nucleoside analog antiviral drugs.
In an IPR, the Burden of Persuasion in an Obviousness Challenge Never Shifts to Patentee
Additional Publications
- August 2017Genentech to Defend 3 of 4 Herceptin® Patents Challenged by Hospira, PTAB Litigation Blog
- March 2017In an IPR, the Burden of Persuasion in an Obviousness Challenge Never Shifts to Patentee
- January 2017Routine Trial-and-Error Approach to Protein Formulation Is Not Sufficient to Establish Obviousness Absent a Reasonable Expectation of Success in Achieving the Claimed Formulation, PTAB Litigation Blog
- University of San Diego (J.D. 2018); Swiss Federal Institute of Technology, ETH-Zurich (Ph.D. in Organic Chemistry 2004; Swiss National Science Foundation Postdoctoral Fellowship); "La Sapienza" University of Rome, Italy (B.A. in Chemistry summa cum laude 1999)
- California and registered to practice before the U.S. Patent and Trademark Office
- Italian